PMID- 38224032
OWN - NLM
STAT- MEDLINE
DCOM- 20240116
LR  - 20240116
IS  - 1110-4902 (Print)
VI  - 31
IP  - 1
DP  - 2024 Jan
TI  - Assessment of Tenascin C levels in the serum of patients with bronchial asthma.
PG  - 20-29
AB  - Asthma is a heterogeneous disease that affects a large proportion of the global 
      population and is distinguished by airway hyperresponsiveness to direct and 
      indirect stimulations. It is a multifactorial disease that is triggered by 
      heredity and environmental causes. Tenascin C (TNC) is an extracellular matrix 
      glycoprotein that promotes inflammatory cell migration from the interstitium to 
      the airways. Stimulation of TNC is through cytokines from T helper 2 (Th2) cells, 
      in addition, it proliferates within basement membranes of the airways in 
      asthmatic patients. This study aimed to determine whether serum TNC can be used 
      as a novel biomarker for asthma diagnosis and to evaluate the association between 
      serum TNC measurement and asthma severity. This case-control study included 64 
      patients with mild to severe bronchial asthma, diagnosed according to GINA 2022, 
      referred to the Allergy and Clinical Immunology outpatient clinic at Ain Shams 
      University Hospital, and 64 normal subjects as controls. Serum TNC levels were 
      measured by ELISA. Serum TNC levels were significantly higher among bronchial 
      asthma patients than controls (p <0.001). The sensitivity of serum TNC 
      measurement in the diagnosis of bronchial asthma was 93.75%, the specificity 
      60.94%, and the negative predictive value 90.7%. Besides, a significant relation 
      was found between serum TNC levels and the severity of bronchial asthma 
      (p=0.004), as elevated serum TNC levels were the highest among severe asthmatic 
      patients. In conclusion, the results gained in this study revealed that serum TNC 
      level could be proposed as a potential biomarker for the diagnosis of bronchial 
      asthma and a potential predictor of disease severity.
CI  - Copyright(c) by the Egyptian Association of Immunologists.
FAU - Elgendy, Aya
AU  - Elgendy A
AD  - Department of Internal Medicine, Allergy and Clinical Immunology, Faculty of 
      Medicine, Ain Shams University, Cairo, Egypt.
FAU - El-Shayeb, Mohamed
AU  - El-Shayeb M
AD  - Department of Internal Medicine, Allergy and Clinical Immunology, Faculty of 
      Medicine, Ain Shams University, Cairo, Egypt.
FAU - Hassanein, Yasmine A
AU  - Hassanein YA
AD  - Department of Internal Medicine, Allergy and Clinical Immunology, Faculty of 
      Medicine, Ain Shams University, Cairo, Egypt.
FAU - Elkady, Hossam M
AU  - Elkady HM
AD  - Department of Internal Medicine, Allergy and Clinical Immunology, Faculty of 
      Medicine, Ain Shams University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PL  - Egypt
TA  - Egypt J Immunol
JT  - The Egyptian journal of immunology
JID - 9816016
RN  - 0 (Tenascin)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Tenascin
MH  - Case-Control Studies
MH  - *Asthma/diagnosis/genetics
MH  - Biomarkers
MH  - Extracellular Matrix
EDAT- 2024/01/15 12:42
MHDA- 2024/01/16 06:42
CRDT- 2024/01/15 07:10
PHST- 2024/01/16 06:42 [medline]
PHST- 2024/01/15 12:42 [pubmed]
PHST- 2024/01/15 07:10 [entrez]
PST - ppublish
SO  - Egypt J Immunol. 2024 Jan;31(1):20-29.